CN112888698A - 2’-卤代-4’-硫代-2’-脱氧-5-氮杂胞苷类似物及其使用方法 - Google Patents

2’-卤代-4’-硫代-2’-脱氧-5-氮杂胞苷类似物及其使用方法 Download PDF

Info

Publication number
CN112888698A
CN112888698A CN201980062607.3A CN201980062607A CN112888698A CN 112888698 A CN112888698 A CN 112888698A CN 201980062607 A CN201980062607 A CN 201980062607A CN 112888698 A CN112888698 A CN 112888698A
Authority
CN
China
Prior art keywords
compound
cancer
administration
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980062607.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·莫里斯
D·G·维什卡
O·D·洛佩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN112888698A publication Critical patent/CN112888698A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201980062607.3A 2018-09-25 2019-09-23 2’-卤代-4’-硫代-2’-脱氧-5-氮杂胞苷类似物及其使用方法 Pending CN112888698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736246P 2018-09-25 2018-09-25
US62/736,246 2018-09-25
PCT/US2019/052410 WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Publications (1)

Publication Number Publication Date
CN112888698A true CN112888698A (zh) 2021-06-01

Family

ID=68136598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062607.3A Pending CN112888698A (zh) 2018-09-25 2019-09-23 2’-卤代-4’-硫代-2’-脱氧-5-氮杂胞苷类似物及其使用方法

Country Status (7)

Country Link
US (2) US20220033387A1 (https=)
EP (1) EP3856754A1 (https=)
JP (1) JP7520822B2 (https=)
CN (1) CN112888698A (https=)
AU (1) AU2019349424B2 (https=)
CA (1) CA3110224A1 (https=)
WO (1) WO2020068657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用
EP4138843A4 (en) * 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
CN114644668B (zh) * 2020-12-18 2026-04-14 鲁南制药集团股份有限公司 一种合成地西他滨的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282986A (zh) * 2005-09-29 2008-10-08 苏伯俭股份有限公司 其中结合5-氮杂-胞嘧啶的寡核苷酸类似物
CN103172662A (zh) * 2004-10-25 2013-06-26 德克技术公司 作为抗肿瘤剂的异磷酰胺氮芥及其类似物的盐
CN103626765A (zh) * 2012-08-27 2014-03-12 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
JP5616968B2 (ja) 2009-12-18 2014-10-29 株式会社リブラメディシーナ 置換された１−Ｏ−アシル−２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノース類の製造方法
AU2013241341B2 (en) 2012-03-28 2016-09-08 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
DK2883866T3 (da) 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172662A (zh) * 2004-10-25 2013-06-26 德克技术公司 作为抗肿瘤剂的异磷酰胺氮芥及其类似物的盐
CN101282986A (zh) * 2005-09-29 2008-10-08 苏伯俭股份有限公司 其中结合5-氮杂-胞嘧啶的寡核苷酸类似物
CN103626765A (zh) * 2012-08-27 2014-03-12 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOZHOK, T. S.: "Synthesis, Hydrolytic Stability, and Antileukemic Activity of Azacytidine Nucleoside Analogs", PHARMACEUTICAL CHEMISTRY JOURNAL, 31 December 2016 (2016-12-31), pages 804 - 809 *
DAIFUKU, RICHARD: "5-aza-2\'2\'-difluroro deoxycytidine (NUC013): a novel nucleoside DNA methyl transferase inhibitor and ribonucleotide reductase inhibitor for the treatment of cancer", PHARMACEUTICALS, 31 December 2017 (2017-12-31), pages 1 - 65 *
THOTTASSERY, JAIDEEP V: "Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4\'-thio-2\'-deoxycytidine and 5-aza-4\'-thio-2\'-deoxycytidine", CANCER CHEMOTHERAPY AND PHARMACOLOGY, 31 December 2014 (2014-12-31), pages 291 - 302 *
TIWARI, KAMAL N.: "Synthesis and Anti-cancer Activity of Some Novel 5-Azacytosine Nucleosides", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 31 December 2003 (2003-12-31), pages 2161 - 2170, XP055221323, DOI: 10.1081/NCN-120026872 *

Also Published As

Publication number Publication date
EP3856754A1 (en) 2021-08-04
JP2022502378A (ja) 2022-01-11
US20220033387A1 (en) 2022-02-03
AU2019349424B2 (en) 2024-04-04
CA3110224A1 (en) 2020-04-02
US11254662B2 (en) 2022-02-22
JP7520822B2 (ja) 2024-07-23
WO2020068657A8 (en) 2021-03-18
AU2019349424A1 (en) 2021-03-18
US20210292310A1 (en) 2021-09-23
WO2020068657A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
RU2746045C2 (ru) Кристалл пирролопиримидина для получения jak-ингибитора
ES2698298T3 (es) Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
JP6317319B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の固体形態
CN102485721B (zh) 取代的2,3-二氮杂萘酮化合物及其用途
CN104473933A (zh) Jak-2 介导的病症的治疗
US20190054097A1 (en) Compositions targeting senescent cells and the uses thereof
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
AU2017263785B2 (en) Oxaborole esters and uses thereof
JP2020509014A (ja) １−（４−｛［６−アミノ−５−（４−フェノキシ−フェニル）−ピリミジン−４−イルアミノ］−メチル｝−ピペリジン−１−イル）−プロペノンの新規結晶形態
TW201639824A (zh) 新穎水溶性前藥
ES2766324T3 (es) Formas salinas de Alfa-TEA: composiciones y usos para tratar enfermedades
CN101511375B (zh) L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
CN101787064A (zh) 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
JP5149168B2 (ja) Ｌｆｍａｕおよびｌｄｔを用いる癌および他の症状または病状の処置方法
KR20080032260A (ko) 결정형 및 무정형 형태의 베타-ｌ-2'-데옥시티미딘
KR20210013081A (ko) 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형
CN105143197A (zh) 新的晶体形式
DE102006037786A1 (de) Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
TW200835505A (en) 2-{[2-(substituted amion)ethyl]sulfonyl}ethyl N, N, N', N'-tetrakis(2-chloroethyl)phosphorodiamidates
CA3018991C (en) Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
CN115260107A (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
HK1260703A1 (en) Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
HK1129844B (en) Use of l-cytosine nucleoside analogs in the manufacture of a medicament for use in treating cancer and other conditions or disease states

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210601

RJ01 Rejection of invention patent application after publication